ArticleNeuro-oncology2019
Regorafenib in advanced high-grade glioma: a retrospective bicentric analysis.
Article in Neuro-oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Current evidence and challenges of multitarget anti-angiogenic agents for glioblastoma: Results from clinical trials.iScience · 2025Review
- Prognostic impact of hand-foot skin reaction in regorafenib-treated adult-type diffuse gliomas: A multicenter Turkish Oncology Group study.Scientific reports · 2025Article
- Genome-wide CRISPR-Cas9 screens identify BCL family members as modulators of response to regorafenib in experimental glioma.Neuro-oncology · 2025Article
- Current status of precision oncology in adult glioblastoma.Molecular oncology · 2024Review
- Just a spoonful of metformin helps the medicine go down.The Journal of clinical investigation · 2024Article
- Antiangiogenic Therapy for Malignant Brain Tumors: Does It Still Matter?Current oncology reports · 2023Review
- Clinical activity of regorafenib in elderly patients with recurrent glioblastoma.Molecular and clinical oncology · 2023Article
- Observational real-life study on regorafenib in recurrent glioblastoma: does dose reduction reduce toxicity while maintaining the efficacy?Journal of neuro-oncology · 2022Observational
- Regorafenib for recurrent high-grade glioma: a unicentric retrospective analysis of feasibility, efficacy, and toxicity.Neurosurgical review · 2022Article
- Efficacy and tolerability of regorafenib in pretreated patients with progressive CNS grade 3 or 4 gliomas.Journal of neuro-oncology · 2022Article
- Regorafenib in Recurrent Glioblastoma Patients: A Large and Monocentric Real-Life Study.Cancers · 2021Article
- Regorafenib CSF Penetration, Efficacy, and MRI Patterns in Recurrent Malignant Glioma Patients.Journal of clinical medicine · 2019Article
- Regorafenib in glioblastoma recurrence: how to deal with conflicting 'real-life' experiences?Therapeutic advances in medical oncology · 2019Article
- Imaging findings following regorafenib in malignant gliomas: FET PET adds valuable information to anatomical MRI.Neuro-oncology advancesArticle
- Feasibility and tolerability of trofosfamide and etoposide in progressive glioblastoma.Neuro-oncology advancesArticle
- Regorafenib beyond the Second Line in Relapsed Glioblastoma: A Case Report and Literature Review.Case reports in oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.